Home › Companies › KARYOPHARM THERAPEUTICS INC. › 2023-2024
Compiled from SEC Form N-PX filings and KARYOPHARM THERAPEUTICS INC.’s Form 8-K, filed 2024-05-31 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2023-2024
Explore KARYOPHARM THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are KARYOPHARM THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-05-31 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Deepika R. Pakianathan | 55,942,175 | -- | -- | 11,898,716 | 22,984,379 | Majority: yes |
| Elect Director: Richard Paulson, M.B.A. | 56,105,696 | -- | -- | 11,735,195 | 22,984,379 | Majority: yes |
| Elect Director: Chen Schor, M.B.A., C.P.A. | 46,571,888 | -- | -- | 21,269,003 | 22,984,379 | Majority: yes |
| 2. The Company's stockholders approved an amendment to the Karyopharm Therapeutics Inc. | 48,577,256 | 19,162,909 | 100,726 | -- | 22,984,379 | Majority: yes |
| 3. The Company's stockholders approved an amendment to the Karyopharm Therapeutics Inc. | 55,691,108 | 12,052,192 | 97,591 | -- | 22,984,379 | Majority: yes |
| 4. The Company's stockholders approved a one-time stock option exchange program for non-executive officer employees. | 60,719,931 | 7,070,865 | 50,095 | -- | 22,984,379 | Majority: yes |
| 5. The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. | 55,719,917 | 12,055,044 | 65,930 | -- | 22,984,379 | Majority: yes |
| 6. The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. | 87,747,448 | 2,519,068 | 558,754 | -- | -- | Majority: yes |
Source: KARYOPHARM THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-05-31 — read the filing on EDGAR.
Each item below shows how the 122 asset managers that disclosed a KARYOPHARM THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of KARYOPHARM THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
KARYOPHARM THERAPEUTICS INC.’s own tally for this item (“5. The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”): 55,719,917 for, 12,055,044 against, per its Form 8-K filed 2024-05-31 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 117,710,263 outstanding shares: 47.3% for, 10% against (58% of the company cast a for/against vote).
The 121 asset managers below cast 99.9% of the shares they voted on this item FOR (46,818,360 for, 14,573 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Avidity Partners Management LP | 8,298,570 | 0 | 0 | 0 | For |
| Vanguard | 8,218,171 | 0 | 0 | 0 | For |
| Palo Alto Investors LP | 5,102,193 | 0 | 0 | 0 | For |
| BlackRock | 4,157,908 | 0 | 0 | 0 | For |
| Citadel | 2,747,093 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 2,630,040 | 0 | 0 | 0 | For |
| C WorldWide Asset Management Fondsmaeglerselskab A/S | 1,500,000 | 0 | 0 | 0 | For |
| State Street | 1,266,023 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Goldman Sachs | 1,007,026 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 900,000 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 868,130 | 0 | 0 | 0 | For |
| DE Shaw | 756,609 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
| UBS | 628,256 | 0 | 0 | 0 | For |
| Charles Schwab | 619,818 | 0 | 0 | 0 | For |
| Northern Trust | 559,637 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 500,000 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 476,413 | 0 | 0 | 0 | For |
| SEI | 421,908 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 369,302 | 0 | 0 | 0 | For |
| Equitable | 227,811 | 0 | 0 | 0 | For |
| ETF Series Solutions | 211,477 | 0 | 0 | 0 | For |
| AllianceBernstein | 192,810 | 0 | 0 | 0 | For |
Showing the 25 largest of 121 asset managers. See all 121 in the interactive database.
Combines 3 wordings of this item as funds reported it.
92% fund support · no official result
The 41 asset managers below cast 92% of the shares they voted on this item FOR (17,748,554 for, 1,569,653 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,168,321 | 0 | 0 | 0 | For |
| Palo Alto Investors LP | 5,102,193 | 0 | 0 | 0 | For |
| BlackRock | 1,719,469 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 500,000 | 0 | 0 | Against |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| Equitable | 35,001 | 192,810 | 0 | 0 | Against |
| ETF Series Solutions | 0 | 211,477 | 0 | 0 | Against |
| SEI | 210,720 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 189,500 | 0 | 0 | Against |
| Fidelity | 75,903 | 51,077 | 0 | 0 | For |
| Lincoln Financial | 94,162 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 89,853 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 68,269 | 0 | 0 | 0 | For |
| AQR | 0 | 64,636 | 0 | 0 | Against |
| Northern Trust | 0 | 43,876 | 0 | 0 | Against |
| Voya | 0 | 38,802 | 0 | 0 | Against |
| Pacific Life | 36,860 | 0 | 0 | 0 | For |
| John Hancock | 0 | 35,868 | 0 | 0 | Against |
| GPS Funds I | 0 | 29,892 | 0 | 0 | Against |
| ProShares | 0 | 23,266 | 0 | 0 | Against |
| Bridge Builder Trust | 19,862 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 17,929 | 0 | 0 | Against |
| DWS | 0 | 17,768 | 0 | 0 | Against |
Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.
Combines 4 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
KARYOPHARM THERAPEUTICS INC.’s own tally for this item (“4. The Company's stockholders approved a one-time stock option exchange program for non-executive officer employees.”): 60,719,931 for, 7,070,865 against, per its Form 8-K filed 2024-05-31 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 117,710,263 outstanding shares: 51.6% for, 6% against (58% of the company cast a for/against vote).
The 40 asset managers below cast 99.3% of the shares they voted on this item FOR (16,737,601 for, 108,453 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,168,321 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 2,630,040 | 0 | 0 | 0 | For |
| BlackRock | 1,719,469 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| Equitable | 227,811 | 0 | 0 | 0 | For |
| ETF Series Solutions | 211,477 | 0 | 0 | 0 | For |
| SEI | 210,720 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 189,500 | 0 | 0 | 0 | For |
| Fidelity | 126,980 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 94,162 | 0 | 0 | Against |
| Goldman Sachs | 89,853 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 68,269 | 0 | 0 | 0 | For |
| AQR | 64,636 | 0 | 0 | 0 | For |
| Northern Trust | 43,876 | 0 | 0 | 0 | For |
| Voya | 38,802 | 0 | 0 | 0 | For |
| Pacific Life | 36,860 | 0 | 0 | 0 | For |
| John Hancock | 35,868 | 0 | 0 | 0 | For |
| GPS Funds I | 29,892 | 0 | 0 | 0 | For |
| ProShares | 23,266 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 19,862 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 17,929 | 0 | 0 | 0 | For |
| DWS | 17,768 | 0 | 0 | 0 | For |
Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.
Combines 5 wordings of this item as funds reported it.
69% Majority: yes · of votes cast
KARYOPHARM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Chen Schor, M.B.A., C.P.A.”): 46,571,888 for, 21,269,003 withheld, per its Form 8-K filed 2024-05-31 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 117,710,263 outstanding shares: 40% for, 18% withheld (58% of the company cast a for/withheld vote).
The 39 asset managers below cast 100% of the shares they voted on this item FOR (13,015,081 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,168,321 | 0 | 0 | 0 | For |
| BlackRock | 1,719,469 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 500,000 | 0 | Abstain |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| Equitable | 35,001 | 0 | 192,810 | 0 | Abstain |
| ETF Series Solutions | 211,477 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 210,720 | 0 | Abstain |
| BRIDGEWAY FUNDS INC | 0 | 0 | 189,500 | 0 | Abstain |
| Fidelity | 126,980 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 94,162 | 0 | Abstain |
| Goldman Sachs | 89,853 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 68,269 | 0 | 0 | 0 | For |
| AQR | 64,636 | 0 | 0 | 0 | For |
| Northern Trust | 43,876 | 0 | 0 | 0 | For |
| Voya | 38,802 | 0 | 0 | 0 | For |
| Pacific Life | 36,860 | 0 | 0 | 0 | For |
| John Hancock | 35,868 | 0 | 0 | 0 | For |
| GPS Funds I | 29,892 | 0 | 0 | 0 | For |
| ProShares | 23,266 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 19,862 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 17,929 | 0 | 0 | 0 | For |
| DWS | 17,768 | 0 | 0 | 0 | For |
| Nationwide | 17,754 | 0 | 0 | 0 | For |
Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.
Combines 5 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
KARYOPHARM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Deepika R. Pakianathan”): 55,942,175 for, 11,898,716 withheld, per its Form 8-K filed 2024-05-31 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 117,710,263 outstanding shares: 47.5% for, 10% withheld (58% of the company cast a for/withheld vote).
The 39 asset managers below cast 100% of the shares they voted on this item FOR (14,023,204 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,168,321 | 0 | 0 | 0 | For |
| BlackRock | 1,719,469 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| Equitable | 35,001 | 0 | 192,810 | 0 | Abstain |
| ETF Series Solutions | 211,477 | 0 | 0 | 0 | For |
| SEI | 210,720 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 189,500 | 0 | 0 | 0 | For |
| Fidelity | 126,980 | 0 | 0 | 0 | For |
| Lincoln Financial | 94,162 | 0 | 0 | 0 | For |
| Goldman Sachs | 89,853 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 68,269 | 0 | 0 | 0 | For |
| AQR | 64,636 | 0 | 0 | 0 | For |
| Northern Trust | 43,876 | 0 | 0 | 0 | For |
| Voya | 38,802 | 0 | 0 | 0 | For |
| Pacific Life | 36,860 | 0 | 0 | 0 | For |
| John Hancock | 35,868 | 0 | 0 | 0 | For |
| GPS Funds I | 29,892 | 0 | 0 | 0 | For |
| ProShares | 23,266 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 19,862 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 17,929 | 0 | 0 | 0 | For |
| DWS | 17,768 | 0 | 0 | 0 | For |
| Nationwide | 17,754 | 0 | 0 | 0 | For |
Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.
Combines 5 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
KARYOPHARM THERAPEUTICS INC.’s own tally for this item (“Elect Director: Richard Paulson, M.B.A.”): 56,105,696 for, 11,735,195 withheld, per its Form 8-K filed 2024-05-31 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 117,710,263 outstanding shares: 47.7% for, 10% withheld (58% of the company cast a for/withheld vote).
The 39 asset managers below cast 100% of the shares they voted on this item FOR (14,216,014 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,168,321 | 0 | 0 | 0 | For |
| BlackRock | 1,719,469 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| Equitable | 227,811 | 0 | 0 | 0 | For |
| ETF Series Solutions | 211,477 | 0 | 0 | 0 | For |
| SEI | 210,720 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 189,500 | 0 | 0 | 0 | For |
| Fidelity | 126,980 | 0 | 0 | 0 | For |
| Lincoln Financial | 94,162 | 0 | 0 | 0 | For |
| Goldman Sachs | 89,853 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 68,269 | 0 | 0 | 0 | For |
| AQR | 64,636 | 0 | 0 | 0 | For |
| Northern Trust | 43,876 | 0 | 0 | 0 | For |
| Voya | 38,802 | 0 | 0 | 0 | For |
| Pacific Life | 36,860 | 0 | 0 | 0 | For |
| John Hancock | 35,868 | 0 | 0 | 0 | For |
| GPS Funds I | 29,892 | 0 | 0 | 0 | For |
| ProShares | 23,266 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 19,862 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 17,929 | 0 | 0 | 0 | For |
| DWS | 17,768 | 0 | 0 | 0 | For |
| Nationwide | 17,754 | 0 | 0 | 0 | For |
Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.
Combines 2 wordings of this item as funds reported it.
100% fund support · no official result
The 39 asset managers below cast 100% of the shares they voted on this item FOR (14,216,014 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,168,321 | 0 | 0 | 0 | For |
| BlackRock | 1,719,469 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| Equitable | 227,811 | 0 | 0 | 0 | For |
| ETF Series Solutions | 211,477 | 0 | 0 | 0 | For |
| SEI | 210,720 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 189,500 | 0 | 0 | 0 | For |
| Fidelity | 126,980 | 0 | 0 | 0 | For |
| Lincoln Financial | 94,162 | 0 | 0 | 0 | For |
| Goldman Sachs | 89,853 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 68,269 | 0 | 0 | 0 | For |
| AQR | 64,636 | 0 | 0 | 0 | For |
| Northern Trust | 43,876 | 0 | 0 | 0 | For |
| Voya | 38,802 | 0 | 0 | 0 | For |
| Pacific Life | 36,860 | 0 | 0 | 0 | For |
| John Hancock | 35,868 | 0 | 0 | 0 | For |
| GPS Funds I | 29,892 | 0 | 0 | 0 | For |
| ProShares | 23,266 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 19,862 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 17,929 | 0 | 0 | 0 | For |
| DWS | 17,768 | 0 | 0 | 0 | For |
| Nationwide | 17,754 | 0 | 0 | 0 | For |
Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.
Combines 2 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
KARYOPHARM THERAPEUTICS INC.’s own tally for this item (“6. The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 87,747,448 for, 2,519,068 against, per its Form 8-K filed 2024-05-31 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 117,710,263 outstanding shares: 75% for, 2% against (77% of the company cast a for/against vote).
The 39 asset managers below cast 100% of the shares they voted on this item FOR (14,216,014 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,168,321 | 0 | 0 | 0 | For |
| BlackRock | 1,719,469 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,125,000 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 740,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| Charles Schwab | 309,909 | 0 | 0 | 0 | For |
| Equitable | 227,811 | 0 | 0 | 0 | For |
| ETF Series Solutions | 211,477 | 0 | 0 | 0 | For |
| SEI | 210,720 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 189,500 | 0 | 0 | 0 | For |
| Fidelity | 126,980 | 0 | 0 | 0 | For |
| Lincoln Financial | 94,162 | 0 | 0 | 0 | For |
| Goldman Sachs | 89,853 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 68,269 | 0 | 0 | 0 | For |
| AQR | 64,636 | 0 | 0 | 0 | For |
| Northern Trust | 43,876 | 0 | 0 | 0 | For |
| Voya | 38,802 | 0 | 0 | 0 | For |
| Pacific Life | 36,860 | 0 | 0 | 0 | For |
| John Hancock | 35,868 | 0 | 0 | 0 | For |
| GPS Funds I | 29,892 | 0 | 0 | 0 | For |
| ProShares | 23,266 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 19,862 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 17,929 | 0 | 0 | 0 | For |
| DWS | 17,768 | 0 | 0 | 0 | For |
| Nationwide | 17,754 | 0 | 0 | 0 | For |
Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.
Ranked by the number of KARYOPHARM THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 117,710,263 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Avidity Partners Management LP | 7.05% |
| 2 | Vanguard | 6.98% |
| 3 | Palo Alto Investors LP | 4.33% |
| 4 | BlackRock | 3.53% |
| 5 | Citadel | 2.33% |
| 6 | Eversept Partners, LP | 2.23% |
| 7 | C WorldWide Asset Management Fondsmaeglerselskab A/S | 1.27% |
| 8 | State Street | 1.08% |
| 9 | MUTUAL FUND SERIES TRUST | 0.96% |
| 10 | Goldman Sachs | 0.86% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Highbridge Capital Management, LLC | 8.28% | DEF14A |
| The Vanguard Group | 7.40% | 13G |
| J. Wood Capital Advisors LLC | 5.84% | DEF14A |
| S | 4.03% | 13G |
| Geode Capital | 2.14% | 13F |
| State Street | 1.94% | 13F |
| Millennium Management | 1.01% | 13F |
| Richard Paulson | 1.00% | DEF14A |
| D.E. Shaw | 0.82% | 13F |
| Northern Trust | 0.81% | 13F |
Percentages above are of 117,710,263 shares outstanding, as reported by KARYOPHARM THERAPEUTICS INC. on its Form 10-Q dated 2024-05-03 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KARYOPHARM THERAPEUTICS INC.’s 10-Q dated 2024-05-03. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At KARYOPHARM THERAPEUTICS INC.'s shareholder meeting held 2024-05-29, in the 2023-2024 proxy season, 122 asset managers reported how they voted in their SEC Form N-PX filings, covering 942 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers. — FOR was 82% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: KARYOPHARM THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-05-31.
KARYOPHARM THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).